Reata Pharma (RETA) Tops Q3 EPS by 10c

Reata Pharma (NASDAQ: RETA) reported Q3 EPS of ($0.04), $0.10 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $12.55 million versus the consensus estimate of $12.46 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Newmarket (NEU) Reports Q1 EPS of $11.23
• First Bancorp. (FBNC) Misses Q1 EPS by 2c